Study to determine the durability of glycaemic control with early treatment with a vildagliptin–metformin combination regimen vs. standard‐of‐care metformin monotherapy—the VERIFY trial: a randomized double‐blind trial-Reference-Cited by-同舟云学术

Study to determine the durability of glycaemic control with early treatment with a vildagliptin–metformin combination regimen vs. standard‐of‐care metformin monotherapy—the VERIFY trial: a randomized double‐blind trial

Published:2014-07-17 Issue:10 Volume:31 Page:1178-1184
ISSN:0742-3071
Container-title:Diabetic Medicine
language:en
Short-container-title:Diabet. Med.

Author:

Del Prato S.¹,Foley J. E.²,Kothny W.²,Kozlovski P.³,Stumvoll M.⁴,Paldánius P. M.³,Matthews D. R.⁵⁶⁷

Affiliation:

1. Department of Endocrinology and Metabolism Section of Metabolic Diseases and Diabetes University of Pisa Pisa Italy

2. Novartis Pharmaceutical Cooperation Clinical Research and Development East Hanover NJ USA

3. Novartis Pharma AG Basel Switzerland

4. Department of Medicine University of Leipzig Germany

5. Oxford Centre for Diabetes Endocrinology and Metabolism Oxford UK

6. National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Oxford UK

7. Harris Manchester College Oxford UK

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dme.12508

Reference19 articles.

1. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

2. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events

3. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

4. Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT

5. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia*

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-Driven Solutions: Integrating Vildagliptin and Dapagliflozin in Diabetes Management;International Journal of Diabetes and Endocrinology;2024-05-10

2. A Randomized, Two-Treatments, Two-Periods, Crossover, Open label, Laboratory-Blind, Single Dose Bioequivalence Study between Vildagliptin/Metformin 50 mg/1000 mg Film Coated Tablets (Sensityn^®) and Galvusmet^® 50 mg/1000 mg Film Coated Tablets in healthy adults under fed conditions;European Pharmaceutical Journal;2023-10-20

3. First-phase insulin secretion: can its evaluation direct therapeutic approaches?;Trends in Endocrinology & Metabolism;2023-04

4. Muscle strength, an independent determinant of glycemic control in older adults with long-standing type 2 diabetes: a prospective cohort study;BMC Geriatrics;2021-12

5. Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus;Diabetes & Metabolism Journal;2021-11-30